JMP Securities Reiterates Market Outperform on BioAtla, Maintains $12 Price Target
Portfolio Pulse from richadhand@benzinga.com
JMP Securities analyst Reni Benjamin has reiterated a 'Market Outperform' rating on BioAtla (NASDAQ:BCAB) and maintained a $12 price target.
August 04, 2023 | 11:21 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BioAtla's stock rating has been reiterated as 'Market Outperform' by JMP Securities, with a maintained price target of $12.
The reiteration of the 'Market Outperform' rating and the maintenance of the $12 price target by JMP Securities indicates a positive outlook for BioAtla. This could potentially lead to an increase in investor confidence and a positive impact on the stock's short-term price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100